Healthcare spending to lift Duopharma


Public-sector segment’s revenue contribution for Duopharma was 50% and 44% in FY24 and FY23, respectively.

PETALING JAYA: TA Research expects Duopharma Biotech Bhd’s revenue from its public-sector segment to increase to 53% this year (FY25) following a recent contract win to supply additional products to the government via Pharmaniaga Logistics Sdn Bhd.

Public-sector segment’s revenue contribution for Duopharma was 50% and 44% in FY24 and FY23, respectively.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Trump hikes US global tariff rate to 15%
The parcel overhang
Zero abandoned homes�by�2030?
Unmasking housing market pricing abuses
Ringgit likely to trade cautiously next week ahead of key US data
Powering a new reinvestment cycle as demand surges
Up in Arms - or up the value chain?
Asia bonds for diversification
AI disruption fears rock markets
Private equity hits a sixer

Others Also Read